Kainosmed, a new drug company for brain disease treatment, announced on the 6th that it is imminent for the approval of the AIDS treatment ‘ACC008’ in China.
‘ACC008’ is a product made from ‘ACC007’, which was approved last year, and the drugs of tenofovir (TDF) and lamivudine (3TC), which are prescribed for the treatment of AIDS, into a single complex tablet. There is no need to take other anti-AIDS drugs, only ‘ACC008’ needs to be taken 1 tablet a day, so it has the advantage of reducing the burden of taking the drug and improving compliance.
Currently, four major anti-AIDS drugs are prescribed in the Chinese market, but they are all imported drugs, which are expensive and must be purchased at your own expense. As ‘ACC008’ is the only single tablet drug produced in China, it is expected that it will be able to secure market share through price competitiveness when entering the market.
ACC007, which started selling as a new drug in China this year, is also listed in health insurance, raising expectations that sales will continue to increase. Kainos Med is receiving royalties on sales of ‘ACC007’, and the sales growth rate in the second quarter of this year jumped 8 times compared to the first quarter of this year.
An official from Kainos Med said, “It seems that there will be positive news regarding the marketing approval from Longevity ID, a Chinese partner. Therefore, when ‘ACC008’ is also launched, the growth of royalties that Kainos Med will receive through ‘ACC007 & ACC008’ is expected to accelerate, and the scale is also expected to increase.”
He added, “We are promoting the transfer of copyrights and technology with other countries besides China, so we are expecting the global sales of Kainos Med’s ‘KM-023’ to grow further.”
